Table 4.

Overview of the biological myelon dose for both 0.1 % and 1.0 % of the myelon volume considering the variable and the constant RBE in both cases with postradiotherapeutic myelopathy.

Case with Myelopathy near T6/7	${\mathit{D}}_{\mathbf{0.1}\mathbf{\%}} \mathbf{\left[}\mathit{G}\mathit{y}\mathbf{\left(}\mathit{R}\mathit{B}\mathit{E}\mathbf{\right)}\mathbf{\right]}$	${\mathit{D}}_{\mathbf{1.0}\mathbf{\%}}\mathbf{\left[}\mathit{G}\mathit{y}\mathbf{\left(}\mathit{R}\mathit{B}\mathit{E}\mathbf{\right)}\mathbf{\right]}$
$\mathrm{cRBE}$	$35.68$	$33.56$
$\mathrm{vRBE}$	$37.65$	$36.91$
Case with myelopathy near T12
$\mathrm{cRBE}$	$22.07$	$22.03$
$\mathrm{vRBE}$	$25.20$	$25.04$
Case with myelopathy near T6/7	$D_{0.1\%} \left[Gy\left(RBE\right)\right]$	$D_{1.0\%}\left[Gy\left(RBE\right)\right]$
$\mathrm{cRBE}$	$35.68$	$33.56$
$\mathrm{vRBE}$	$37.65$	$36.91$
Case with myelopathy near T12
$\mathrm{cRBE}$	$22.07$	$22.03$
$\mathrm{vRBE}$	$25.20$	$25.04$